We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toVirtual-Audits-Do-They-Achieve-the-Objective

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.


Virtual Audits: Do They Achieve the Objective?

    Session Chair(s)
      Sarah Ann  Silvers, MS

      Sarah Ann Silvers, MS

      • Director, GCP Process Control and Compliance
      • Ce3, United States
    The purpose of this session will be to bring industry and regulatory authorities together to discuss expectations and interpretation of recent risk-based guidance as applied to conducting audits remotely. Currently there are a number of large pharma/ biotech companies that, as part of their oversight obligations, perform audits, some of which are performed remotely. In some cases sponsors have received feedback from regulatory authorities regarding this methodology. Likewise, some regulatory authorities have been conducting GCP audits in a remote fashion (often termed desktop assessment). Case studies and other experience as to whether or not this audit format has served as a quality measure will be discussed.
    Learning Objective : Describe how industry professionals are applying risk-based methodology and employing technology to perform GCP audits without leaving their office; Explain how regulatory authorities are likewise performing (or are considering performing) inspections remotely and determine whether or not this is an acceptable practice to ensure quality oversight.
    Speaker(s)
      Sophie  Moya

      Industry Perspective

      Sophie Moya

      • Quality Assurance Manager, Development, Medical, and Regulatory Affairs
      • Guerbet, France
      Kara  Harrison, MS, RAC

      Industry Perspective

      Kara Harrison, MS, RAC

      • Project Manager
      • FDA Quality and Regulatory Consultants, United States
      Paul E Houri, MBA, MS

      Industry Perspective

      Paul E Houri, MBA, MS

      • Vice President, Quality Assurance
      • Janssen Pharmaceutical Companies of Johnson & Johnson, United States